Repare Raises $68M in Series A to Develop CRISPR-Based Synthetic Lethality Platform

04:26 EDT 22 Jun 2017 | Genetic Engineering News

Versant Venture and MPM Capital co-led a $68 million Series A fundraising round to establish Repare Therapeutics, a Canada-based cancer drug company exploiting a high-throughput, CRISPR-based screening platform to identify synthetic lethality cancer targets and develop precision anticancer therapies. For the last 18 months Repare has been working in stealth mode under Versant incubation to develop its synthetic lethality platform and identify initial oncology targets. The firm says a number of programs have now been moved into preclinical development, and clinical trials with an initial candidate could start in 2019. Additional investors in Repare’s Series A fundraising included Fonds de solidarité FTQ, Celgene Switzerland, and BDC Capital’s Healthcare Venture Fund. “Versant’s commitment to and confidence in Repare’s distinct science has enabled the company to build the team, operations and initial programs away from the spotlight,” said Repare CEO Lloyd M. Segal. “With the added leadership of MPM ...

Original Article: Repare Raises $68M in Series A to Develop CRISPR-Based Synthetic Lethality Platform


More From BioPortfolio on "Repare Raises $68M in Series A to Develop CRISPR-Based Synthetic Lethality Platform"

Quick Search


Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...